Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 920 (MIR920) is a short, non-coding RNA belonging to the microRNA (miRNA) family, typically 20–24 nucleotides in length[5]. miRNAs serve as key post-transcriptional regulators of gene expression in multicellular organisms, mainly by binding to the 3′ untranslated regions (UTRs) of target messenger RNAs (mRNAs), leading to translational repression or mRNA degradation[1][5]. MIR920 is transcribed by RNA polymerase II, processed from a primary transcript (pri-miRNA), and then converted into a precursor miRNA (pre-miRNA), which is ultimately cleaved into the mature form that is incorporated into the RNA-induced silencing complex (RISC)[1][5]. While there are well-established roles for many miRNAs in the regulation of diverse biological processes such as cell proliferation, differentiation, apoptosis, and immune response, there is limited specific information on the direct biological or disease functions of MIR920 itself[5]. It is not considered a therapeutic target (such as a receptor, enzyme, or transporter), but is a member of the broader non-coding RNA regulatory machinery[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 920 (MIR920).